Nutriband Partners with Brand Institute to Develop Global Brand Identity for Abuse-Deterrent Fentanyl Patch

Nutriband Inc. (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, has announced a strategic partnership with Brand Institute, Inc. to develop the global brand identity for AVERSA FENTANYL, the company's lead product utilizing its proprietary AVERSA abuse-deterrent transdermal technology. This collaboration represents a significant step toward potentially introducing the world's first abuse-deterrent opioid patch to the market, addressing critical safety concerns in pain management and opioid prescribing practices.

The partnership brings together Nutriband's innovative pharmaceutical technology with Brand Institute's extensive expertise in pharmaceutical branding and regulatory compliance. Brand Institute maintains a dominant position in the industry, having secured 75% of global drug name approvals and 87% of FDA-approved names in 2024. The initiative will be supported by Brand Institute's regulatory subsidiary, Drug Safety Institute, which employs former officials from major regulatory bodies including the FDA, EMA, Health Canada, USAN, and WHO, ensuring comprehensive regulatory strategy and compliance throughout the branding process.

AVERSA FENTANYL incorporates Nutriband's AVERSA technology, specifically designed to deter misuse and reduce accidental opioid exposure. This technology represents a crucial advancement in transdermal drug delivery systems, as it can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The development comes at a critical time when opioid abuse remains a significant public health concern worldwide, with transdermal patches being particularly vulnerable to misuse through extraction and injection methods.

The global branding initiative for AVERSA FENTANYL through this partnership with Brand Institute aims to establish a strong commercial identity that reflects the product's safety features and therapeutic benefits. As described on the company's website at https://www.nutriband.com, Nutriband is primarily engaged in developing a portfolio of transdermal pharmaceutical products, with AVERSA FENTANYL representing their most advanced product candidate. The collaboration leverages Brand Institute's proven track record in creating successful pharmaceutical brand identities that resonate with healthcare professionals, patients, and regulatory authorities alike.

This development holds particular importance given the ongoing opioid crisis and the need for safer pain management alternatives. The potential introduction of the first abuse-deterrent opioid patch could significantly impact clinical practice by providing healthcare providers with additional tools to balance effective pain management with reduced abuse potential. The partnership's timing aligns with increased regulatory focus on opioid safety and abuse-deterrent formulations, positioning AVERSA FENTANYL to potentially address unmet needs in pain management while contributing to public health efforts to combat opioid misuse and addiction.